Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Immunology (Baltimore, Md. : 1950)|May 22, 2004
Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3Katalin Karikó, Prakash Bhuyan, John Capodici, et al.
Analytical and Bioanalytical Chemistry|June 21, 2024
HPLC-MS/MS-based quantification of human monoclonal antibodies targeting SARS-CoV-2 in the presence of endogenous SARS-CoV-2 antibodies in human serumAlexander Schäfer, Peter Sagelsdorff, Björn Hock, et al.
Cells, Tissues, Organs|September 25, 2004
Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3Katalin Karikó, Prakash Bhuyan, John Capodici, et al.
Drug Discovery Today|November 3, 2015
Repurposing historical control clinical trial data to provide safety contextPrakash Bhuyan, Jigar Desai, Matthew St Louis, et al.
Scientific Reports|May 13, 2022
Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccinationTaylor S Cohen, Elizabeth J Kelly, Sven Nylander, et al.
The Pediatric Infectious Disease Journal|December 19, 2013
Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccineScott A Halperin, Bruce Tapiéro, Marc Dionne, et al.
The Pediatric Infectious Disease Journal|December 18, 2012
Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label studyBruce Tapiéro, Scott A Halperin, Mark Dionne, et al.
Vaccine|August 21, 2022
Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associationsMichael A Laffan, Sue Rees, Madhavi Yadavalli, et al.
The Pediatric Infectious Disease Journal|March 15, 2016
A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US AdolescentsDerek Muse, Shane Christensen, Prakash Bhuyan, et al.
Vaccine|December 29, 2015
Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workersDavid M Reiner, Prakash Bhuyan, Joseph J Eiden, et al.
Pageof 2